Neoleukin Therapeutics Inc.
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
IPO Year: 2014
Exchange: NASDAQ
Website: neoleukin.com
Recent Analyst Ratings for Neoleukin Therapeutics Inc.
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/2/2022 | $30.00 → $25.00 | Overweight | Piper Sandler |
8/6/2021 | $30.00 | Overweight | Piper Sandler |
Neoleukin Therapeutics Inc. Press Releases
Fastest customizable press release news feed in the world
Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split
SEATTLE, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" or the "Company" (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, today announced that its Board of Directors ("Board") has approved a reverse stock split of the Company's outstanding shares of common stock at a ratio of 1-for-4. The reverse stock split will become effective at 12:02 a.m., Eastern Time on December 18, 2023. The Company's common stock is expected to begin trading on a post-reverse stock split basis on the Nasdaq Global Market on December 19, 2023, under the new name Neurogene Inc. and under the new symbo
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
SEATTLE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" or the "Company" (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, today announced that its Board of Directors ("Board") has approved a reverse stock split of the Company's outstanding shares of common stock at a ratio of 1-for-5. The reverse stock split will become effective at 12:01 a.m. Eastern time on September 25, 2023. Neoleukin's common stock will begin trading on a post-reverse stock split basis on September 25, 2023, under Neoleukin's existing trading symbol "NLTX" with a new CUSIP number 64049K203. The reverse
Lifshitz Law PLLC Announces Investigations of HCCI, PRDS, NLTX, CCF
NEW YORK, July 22, 2023 (GLOBE NEWSWIRE) -- Heritage-Crystal Clean, Inc. (NASDAQ:HCCI) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of HCCI to an investment affiliate of J.F. Lehman & Company for $45.50 per share in cash for each share of HCCI common stock owned. If you are a HCCI investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com. Pardes Biosciences, Inc. (NASDAQ:PRDS) Lifshitz Law PLLC announces an investigation into possible breach of fiducia
Neurogene and Neoleukin Announce Definitive Merger Agreement
Proposed merger to create Nasdaq-listed biotech company focused on advancing Neurogene's differentiated portfolio of genetic medicines for complex neurological diseases Combined company is expected to have a cash balance of approximately $200 million at close, including approximately $95 million from concurrent private financing by Neurogene's new and existing investors Cash expected to fund combined company into 2H:26 and through multiple catalysts, including preliminary data in 4Q:24 and additional data in 2H:25 from a Phase 1/2 clinical trial in Rett syndrome Companies to host conference call today at 8:30 am ET NEW YORK and SEATTLE, July 18, 2023 (GLOBE NEWSWIRE) -- Neurogene Inc.,
Neoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership Transition
SEATTLE, March 08, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that it has engaged SVB Securities to assist in reviewing strategic alternatives for the Company with the goal of maximizing shareholder value. Such alternatives may include a sale, merger, divestiture of assets, licensing or other strategic transaction. There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or that, if completed, any agreements or transactions will be successful or on attractive te
Neoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual Meeting
SEATTLE, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today presented data on NEO-TRA1, a precision-tuned agonist of the IL-2 receptor beta and gamma subunits that is targeted to and selectively expands inhibitory T-regulatory cells. The data are being disclosed today as an oral presentation at the American Society of Hematology (ASH) Annual Meeting. The presentation highlights two important features of Neoleukin's de novo protein technology: 1) the ability to target de novo cytokine mimetics to specific cell types, i.e. T-regulato
Neoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Update
-- Development of NL-201 to be discontinued for strategic reasons ---- Company to focus on next-generation de novo proteins and core technology ---- Company restructuring to extend cash runway into the second half of 2025 -- SEATTLE, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the third quarter ended September 30, 2022 as well as a strategic decision to discontinue development of NL-201, a fully de novo IL-2/IL-15 agonist, and focus on advancing next-generation de novo protein therapeutics bas
Neoleukin Therapeutics Announces Oral Presentation at 64th American Society of Hematology (ASH) Annual Meeting
SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced an oral presentation at the upcoming American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 10-13, 2022 in New Orleans, Louisiana. Oral presentation details are as follows: Title: NEO-TRA1: A CD25-Targeted De Novo non-Alpha Agonist of the IL-2 Receptor Selectively Expands Regulatory T CellsSession Name: 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Delineating Immunity from Mice to Humans P
Neoleukin Therapeutics Announces Second Quarter 2022 Financial Results & Provides Corporate Update
SEATTLE, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the second quarter ended June 30, 2022 and a midyear corporate update. "Our focus at Neoleukin is the advancement of de novo proteins to solve important therapeutic challenges and address unmet medical needs," said Jonathan Drachman, M.D., Chief Executive Officer of Neoleukin. "We are excited to be part of a revolutionary approach to creating therapeutic proteins that are not based on native sequences. Our first programs, including our lead
Neoleukin Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference
SEATTLE, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022 at 1 p.m. Eastern. The webcast presentation can be accessed from the investors section of the Neoleukin website at http://investor.neoleukin.com/events. An archived replay will also be available on the company website for at least 30 days following the event. About Neoleukin Therapeutics, Inc. Neoleukin is a bi
Neoleukin Therapeutics Inc. Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Piper Sandler reiterated coverage on Neoleukin Therapeutics with a new price target
Piper Sandler reiterated coverage of Neoleukin Therapeutics with a rating of Overweight and set a new price target of $25.00 from $30.00 previously
Piper Sandler resumed coverage on Neoleukin Therapeutics with a new price target
Piper Sandler resumed coverage of Neoleukin Therapeutics with a rating of Overweight and set a new price target of $30.00
Neoleukin Therapeutics Inc. Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
SEC Form 4 filed by Woods Robert Keith
4 - Neurogene Inc. (0001404644) (Issuer)
SEC Form 4 filed by Palekar Rohan
4 - Neurogene Inc. (0001404644) (Issuer)
SEC Form 4 filed by Noonberg Sarah B.
4 - Neurogene Inc. (0001404644) (Issuer)
SEC Form 4 filed by Freedland Cory S.
4 - Neurogene Inc. (0001404644) (Issuer)
SEC Form 4 filed by Baffi Robert
4 - Neurogene Inc. (0001404644) (Issuer)
SEC Form 4 filed by Jordan Julie
4 - Neurogene Inc. (0001404644) (Issuer)
SEC Form 3 filed by new insider Jordan Julie
3 - Neurogene Inc. (0001404644) (Issuer)
New insider Cvijic Christine Mikail claimed ownership of 20,941 shares (SEC Form 3)
3 - Neurogene Inc. (0001404644) (Issuer)
New insider Mcminn Rachel claimed ownership of 1,250,359 shares (SEC Form 3)
3 - Neurogene Inc. (0001404644) (Issuer)
SEC Form 3 filed by new insider Woods Robert Keith
3 - Neurogene Inc. (0001404644) (Issuer)
Neoleukin Therapeutics Inc. SEC Filings
SEC Form 144 filed by Neoleukin Therapeutics Inc.
144 - Neurogene Inc. (0001404644) (Subject)
Neoleukin Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Neurogene Inc. (0001404644) (Filer)
Neoleukin Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Shareholder Director Nominations, Regulation FD Disclosure
8-K - Neurogene Inc. (0001404644) (Filer)
SEC Form 425 filed by Neoleukin Therapeutics Inc.
425 - Neoleukin Therapeutics, Inc. (0001404644) (Subject)
Neoleukin Therapeutics Inc. filed SEC Form 8-K: Other Events
8-K - Neoleukin Therapeutics, Inc. (0001404644) (Filer)
SEC Form 425 filed by Neoleukin Therapeutics Inc.
425 - Neoleukin Therapeutics, Inc. (0001404644) (Subject)
Neoleukin Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - Neoleukin Therapeutics, Inc. (0001404644) (Filer)
SEC Form 425 filed by Neoleukin Therapeutics Inc.
425 - Neoleukin Therapeutics, Inc. (0001404644) (Subject)
SEC Form EFFECT filed by Neoleukin Therapeutics Inc.
EFFECT - Neoleukin Therapeutics, Inc. (0001404644) (Filer)
SEC Form S-4/A filed by Neoleukin Therapeutics Inc. (Amendment)
S-4/A - Neoleukin Therapeutics, Inc. (0001404644) (Filer)
Neoleukin Therapeutics Inc. Leadership Updates
Live Leadership Updates
Neoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership Transition
SEATTLE, March 08, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that it has engaged SVB Securities to assist in reviewing strategic alternatives for the Company with the goal of maximizing shareholder value. Such alternatives may include a sale, merger, divestiture of assets, licensing or other strategic transaction. There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or that, if completed, any agreements or transactions will be successful or on attractive te
Neoleukin Therapeutics Announces First Quarter 2022 Financial Results and Corporate Update
SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the quarter ending March 31, 2022 and provided a corporate update. "During the first quarter of 2022 our dedicated team at Neoleukin has been focused on execution of our NL-201 Phase 1 clinical trial, evaluating multiple schedules during dose escalation in patients with relapsed and refractory solid tumors," said Jonathan Drachman, M.D., Chief Executive Officer of Neoleukin. "We anticipate reporting interim data from this trial during the sec
Neoleukin Therapeutics Announces Appointment of Donna Cochener as General Counsel
SEATTLE, March 15, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Donna M. Cochener as General Counsel, Senior Vice President Legal. Ms. Cochener joins Neoleukin after serving as Senior Vice President, Deputy General Counsel at HomeStreet, Inc., the parent company of HomeStreet Bank. In that role, she was primarily responsible for securities reporting and compliance and corporate governance as well as serving as lead attorney on a range of transactions, including mergers and acquisitions and debt and equit
Neoleukin Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Update
– NL-201 Phase 1 solid tumor trial interim data anticipated in 2022 – – Upcoming presentations at ACR, SITC, and ASH to highlight preclinical data – – Planning to initiate a Phase 1 trial in hematologic malignancies with NL-201 in 2022 – SEATTLE, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results and a corporate update for the third quarter ended September 30, 2021. "During the third quarter, we made progress with our NL-201 phase 1 clinical trial, initiating multiple additional sites
Neoleukin Therapeutics Announces Appointment of Bill Arthur, Ph.D., as Vice President and Head of Research
SEATTLE, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Bill Arthur, Ph.D., as Vice President and Head of Research. Dr. Arthur joins Neoleukin after a decade at Seagen, where he served most recently as Senior Director & Head of Cancer Biology. During his time at Seagen, Dr. Arthur directed research efforts on therapeutic candidates, from discovery through clinical development, utilizing novel platform technologies, including antibody-drug conjugates with cytotoxic and immunostimulatory mechanisms,
Neoleukin Therapeutics Announces Appointment of Priti Patel, M.D., M.S., as Chief Medical Officer
SEATTLE, May 03, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Priti Patel, M.D., M.S., as Chief Medical Officer. Dr. Patel joins Neoleukin from AstraZeneca, where she served as Vice President, Head of Hematology Clinical Development since 2019. Previously, she served as Senior Medical Director and Executive Medical Director at Acerta Pharma before its acquisition by AstraZeneca. During her time at AstraZeneca and Acerta, Dr. Patel led clinical development strategy and trial execution of investigational the
Neoleukin Therapeutics Inc. Financials
Live finance-specific insights
Neurogene and Neoleukin Announce Definitive Merger Agreement
Proposed merger to create Nasdaq-listed biotech company focused on advancing Neurogene's differentiated portfolio of genetic medicines for complex neurological diseases Combined company is expected to have a cash balance of approximately $200 million at close, including approximately $95 million from concurrent private financing by Neurogene's new and existing investors Cash expected to fund combined company into 2H:26 and through multiple catalysts, including preliminary data in 4Q:24 and additional data in 2H:25 from a Phase 1/2 clinical trial in Rett syndrome Companies to host conference call today at 8:30 am ET NEW YORK and SEATTLE, July 18, 2023 (GLOBE NEWSWIRE) -- Neurogene Inc.,
Neoleukin Therapeutics Announces Second Quarter 2022 Financial Results & Provides Corporate Update
SEATTLE, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the second quarter ended June 30, 2022 and a midyear corporate update. "Our focus at Neoleukin is the advancement of de novo proteins to solve important therapeutic challenges and address unmet medical needs," said Jonathan Drachman, M.D., Chief Executive Officer of Neoleukin. "We are excited to be part of a revolutionary approach to creating therapeutic proteins that are not based on native sequences. Our first programs, including our lead
Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022
SEATTLE, July 27, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), today announced it will report second quarter 2022 financial results on Tuesday, August 9, 2022 after the close of financial markets and then host a conference call and live audio webcast to discuss these results and provide a corporate update. Details of the event are as follows: Date: Tuesday, August 9, 2022 Time: 1:30 p.m. Pacific / 4:30 p.m. Eastern Toll-free: (800) 715-9871 Conference ID: 4116795 Webcast URL: http://investor.neoleukin.com/events The archived audio webcast will be available on the Investor Relations section of the Neoleukin website approximately two hours after the
Neoleukin Therapeutics Announces Year End 2021 Financial Results and Corporate Update
- Interim data from NL-201 Phase 1 trial for patients with relapsed and refractory solid tumors anticipated in the second half of 2022 – - $142.5 million in cash and cash equivalents expected to provide runway into the second half of 2023 – - Appointment of Rohan Palekar to Board of Directors – - Company to host conference call today, March 1, 2022 at 1:30 p.m. PT / 4:30 p.m. ET – SEATTLE, March 01, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results and a corporate update for the year ended December 31, 2021.
Neoleukin Therapeutics to Host 2021 Financial Results Conference Call and Webcast on March 1, 2022
SEATTLE, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced , today announced it will report full year 2021 financial results on Tuesday, March 1, 2022 after the close of financial markets and then host a conference call and live audio webcast to discuss these results and provide a corporate update. Details of the event are as follows: Date: March 1, 2022Time: 1:30 p.m. Pacific / 4:30 p.m. EasternToll-free: (866) 357-7878International: (315) 625-3088Conference ID: 8928189Webcast URL: http://investor.neoleukin.com/events
Neoleukin Therapeutics Inc. Large Ownership Changes
This live feed shows all institutional transactions in real time.
SEC Form SC 13G filed by Neoleukin Therapeutics Inc.
SC 13G - Neurogene Inc. (0001404644) (Subject)
SEC Form SC 13G/A filed by Neoleukin Therapeutics Inc. (Amendment)
SC 13G/A - Neurogene Inc. (0001404644) (Subject)
SEC Form SC 13G/A filed by Neoleukin Therapeutics Inc. (Amendment)
SC 13G/A - Neurogene Inc. (0001404644) (Subject)
SEC Form SC 13G filed by Neoleukin Therapeutics Inc.
SC 13G - Neurogene Inc. (0001404644) (Subject)
SEC Form SC 13G filed by Neoleukin Therapeutics Inc.
SC 13G - Neurogene Inc. (0001404644) (Subject)
SEC Form SC 13G filed by Neoleukin Therapeutics Inc.
SC 13G - Neurogene Inc. (0001404644) (Subject)
SEC Form SC 13G/A filed by Neoleukin Therapeutics Inc. (Amendment)
SC 13G/A - Neurogene Inc. (0001404644) (Subject)
SEC Form SC 13G filed by Neoleukin Therapeutics Inc.
SC 13G - Neurogene Inc. (0001404644) (Subject)
SEC Form SC 13G/A filed by Neoleukin Therapeutics Inc. (Amendment)
SC 13G/A - Neurogene Inc. (0001404644) (Subject)
SEC Form SC 13D filed by Neoleukin Therapeutics Inc.
SC 13D - Neurogene Inc. (0001404644) (Subject)